Interchangeable Biosimilars Market Analysis by Disease Type (Crohn's Disease, Ulcerative Colitis, Psoriasis, Diabetes, Cancer, and Others); by Application (Hematology, Oncology, Autoimmune Disease, Chronic, Blood Disorder, and Others); and by Distribution Channel (Hospital, Retail Pharmacies, and Others) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2035

  • Report ID: 4047
  • Published Date: Mar 13, 2023
  • Report Format: PDF, PPT

Companies Dominating the Interchangeable Biosimilars Landscape

top-features-companies
    • Biocon Limited
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Mylan N.V.
    • Amgen Inc.
    • Coherus BioSciences, Inc.
    • Pfizer Inc.
    • Sandoz International GmbH
    • Merck & Co.
    • Boehringer Ingelheim group
    • Samsung Bioepis Co., Ltd.
    • Teva Pharmaceutical Industries Ltd.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Samsung Bioepis Co., Ltd. and Biogen Canada Inc. announced the approval of BYOOVIZ by Health Canada. BYOOVIZ is a biosimilar referencing LUCENTIS (ranibizumab).

  •  Sandoz International GmbH, a global leader in generic and biosimilar medicines, announced the submission of a Biologics License Application for biosimilar trastuzumab to the US Food and Drug Administration (FDA).


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4047
  • Published Date: Mar 13, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing incidences of chronic diseases and the growing availability of over-the-counter drugs along with the rising focus on health and fitness are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 20% over the forecast period, i.e., 2023-2035.

Stringent regulations regarding the approval of biosimilars coupled with high-cost associated with interchangeable biosimilars are estimated to be the growth hindering factors for the market expansion.

The market in the Asia Pacific region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Biocon Limited, Mylan N.V., Amgen Inc., Coherus BioSciences, Inc., Pfizer Inc., Sandoz International GmbH, Merck & Co., Boehringer Ingelheim group, Samsung Bioepis Co., Ltd., Teva Pharmaceutical Industries Ltd., and other key players.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by disease type, application, end-users, and by region.

The cancer segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying